Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121587) titled 'Orelabrutinib combined with rituximab for the treatment of MZL with pss' on April 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Condition:
Marginal zone lymphoma accompanied by Sjogren's syndrome
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-04-01
Target Sample Size: Treatment group:12;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=316539
Disclaimer: Curated by HT Syndication....